Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, 45227, United States
NCT Number: NCT03331900
The study is a randomized, double-blind, placebo-controlled, dose escalation, first-in-human trial of the safety and tolerability of COR388 HCl in healthy male and female subjects.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Cincinnati, Ohio, 45227, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Major Inclusion Criteria:
Major Exclusion Criteria:
Administered as oral capsule
Administered as oral capsule
Time frame: 72 hours
Analysis of AUC
Time frame: 72 hours
Analysis of Cmax
Time frame: 72 hours
Analysis of Tmax
Time frame: 72 Hours
Assessment of the incidence and severity of treatment-emergent adverse events.
Time frame: 72 hours
Assessment of changes in serum chemistry measures.
Time frame: 72 hours
Assessment of changes in hematology measures.
Time frame: 72 hours
Assessment of changes in urinalysis parameters.
Cortexyme Inc.
Industry
A Phase 1 Single Ascending Dose Study of COR388 HCl
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07470125
Healthy Subjects
Seoul, South Korea
View Trial DetailsNCT06818032
Healthy, Healthy Adult
Burlington, Vermont, United States
View Trial DetailsNCT00761631
Healthy Subjects
Benton, Arkansas, United States
View Trial DetailsNCT02610465
Cardiac-Related Conditions, Healthy Subjects
Bethesda, Maryland, United States
View Trial Details